Should an ingredient supplier explicitly target GLP-1 medication users in their B2B communication
629,630 Recent findings have identified ferroptosis in the hippocampus of mice subjected to chronic mild and unpredictable stress (CUMS)-induced major depression, and suggest that the occurrence of depression may be related to ferroptosis-associated pathways
By working collaboratively across the ecosystem, we help ensure that consumers have access to safe and effective solutions and medications. The End of the GLP-1 Shortage In October 2024, the FDA announced that the shortage of tirzepatide, the active ingredient in Mounjaro and Zepbound, was resolved, and shortages of other GLP-1s are also poised to be resolved in the near future
[DOI] [PMC free article] [PubMed] [Google Scholar] 20.Shintani T., Yamada T., Hayashi N., Iida T., Nagata Y., Ozaki N., Toyoda Y